For a 19-year-old patient positive for influenza or COVID-19, should they be treated with Oseltamivir (Tamiflu) or Paxlovid (nirmatrelvir/ritonavir)?

Treatment Recommendations for 19-Year-Old with Influenza or COVID-19

Direct Answer

For influenza: Yes, treat with oseltamivir (Tamiflu) 75 mg twice daily for 5 days if symptomatic within 5 days of onset, even in otherwise healthy young adults. 1, 2 For COVID-19: No, do not routinely treat a healthy 19-year-old with Paxlovid unless they have high-risk conditions (immunocompromised status, significant comorbidities, or unvaccinated status). 3

---

Influenza Treatment with Oseltamivir

When to Treat

Oseltamivir should be initiated immediately for any 19-year-old with suspected or confirmed influenza during flu season, ideally within 48 hours of symptom onset, though treatment beyond 48 hours still provides benefit. 1, 2

• Treatment is most effective when started within 48 hours, reducing illness duration by approximately 17.6-29.9 hours 1, 2
• Even beyond 48 hours, treatment provides substantial benefit in reducing complications and should be strongly considered 1, 2
• Do not wait for laboratory confirmation—initiate treatment empirically based on clinical suspicion during influenza season 2

Expected Clinical Benefits

• Reduces illness duration by 1-1.5 days when started optimally 2
• Decreases risk of pneumonia by 50% 2
• Reduces risk of hospitalization in outpatients 2
• Faster return to normal activities and reduced antibiotic use 2

Dosing for 19-Year-Old

Standard adult dosing: 75 mg orally twice daily for 5 days 1, 2

• No dose adjustment needed for healthy young adults 2
• Take with or without food to minimize nausea 2

Common Adverse Effects

• Nausea and vomiting are most common (occurring in approximately 3.66% and 4.56% more than placebo, respectively) 2
• These effects are transient and rarely lead to discontinuation 1, 2
• No established link between oseltamivir and neuropsychiatric events 2

Critical Pitfall to Avoid

The most common error is delaying or withholding oseltamivir while waiting for laboratory confirmation. 2 Rapid antigen tests have poor sensitivity, and negative results should not exclude treatment during influenza season. 2

---

COVID-19 Treatment with Paxlovid

Risk Stratification is Essential

Paxlovid is NOT routinely indicated for healthy 19-year-olds without risk factors. 3 The drug is specifically recommended for patients at high risk of progression to severe disease. 3

High-Risk Criteria Requiring Paxlovid

Treat with Paxlovid if the 19-year-old has ANY of the following: 3

• Immunocompromised status (hematological malignancies, transplant recipients, HIV, immunosuppressive medications) 3
• Unvaccinated or vaccine non-responders 3
• Significant chronic medical conditions (though less common in this age group) 3

When NOT to Use Paxlovid

Do not prescribe Paxlovid for: 3

• Otherwise healthy, vaccinated 19-year-olds with mild COVID-19 3
• Patients at low or moderate risk of hospitalization 3
• Patients presenting more than 5 days after symptom onset 3

If Paxlovid IS Indicated

Dosing: 300 mg nirmatrelvir with 100 mg ritonavir, taken twice daily for 5 days, started within 5 days of symptom onset 3

Critical Safety Considerations for Paxlovid

Drug-drug interactions are the primary safety concern. 3

• Mandatory: Use the Liverpool COVID-19 Drug Interaction Tool to check for contraindicated medications before prescribing 3
• Ritonavir is a strong CYP3A4 inhibitor causing numerous interactions 3
• Common medications requiring caution include oral contraceptives, statins, anticonvulsants, and immunosuppressants 3
• Interactions persist during treatment and for several days after completion 3

Common Adverse Effects of Paxlovid

• Dysgeusia (altered taste) and diarrhea occur more frequently than placebo 3
• These effects did not lead to increased discontinuation rates in trials 3

---

Evidence Quality and Nuances

Influenza Treatment Evidence

The recommendation for oseltamivir in young adults is based on consistent guideline support from the American Academy of Pediatrics and CDC. 1, 2 While the absolute benefit in otherwise healthy young adults is modest (reducing illness by approximately 1 day), the safety profile is excellent and treatment is widely recommended during influenza season. 1, 2

COVID-19 Treatment Evidence

The evidence strongly supports Paxlovid only for high-risk patients. 3 Recent high-quality observational data from 2025 showed Paxlovid reduced hospitalization risk by 39% and death by 61% in appropriate populations. 4 However, guidelines explicitly recommend against routine use in low-risk patients, where benefits do not outweigh costs and potential harms. 3

Important: Oseltamivir is NOT effective against COVID-19 and should never be used for this indication. 5 In vitro studies and clinical case analyses confirmed oseltamivir has no activity against SARS-CoV-2. 5

Equity Considerations

For both conditions, treatment decisions should not be influenced by race, ethnicity, or socioeconomic status—clinical risk factors alone should guide therapy. 4 However, be aware that disparities in Paxlovid prescription rates exist, with lower rates among Black and Hispanic patients despite similar clinical indications. 4